| 2025-12-14 |
详情>>
内部人交易：
Mehta Vimal共交易2笔
|
| 2025-11-12 |
股东大会：
将于2025-12-12召开股东大会
会议内容 ▼▲
- 1.To elect June Bray, Sandeep Laumas, M.D. and David Mack, as Class I directors to hold office until the Company’s annual meeting of stockholders to be held in 2028 and until their respective successors have been duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2025;
3.To approve, on an advisory (non-binding) basis, the compensation of our named executive officers (“Say-on-Pay Vote”);
4.To approve an amendment to our Amended and Restated Certificate of Incorporation, as amended (“Certificate of Incorporation”) to effect, within 12 months following the date of stockholder approval and solely if the Board determines that it is necessary and advisable to regain* compliance with the minimum bid price requirements of the Nasdaq Capital Market, a reverse stock split at a ratio of not less than 1-for-2 and not greater than 1-for-20, with the exact ratio to be set within that range by the Board (the “Reverse Stock Split Proposal”);
5.To authorize one or more adjournments of the Annual Meeting to solicit additional proxies in the event there are insufficient votes to approve Proposal 4 described above (the “Adjournment Proposal”);
6.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment thereof.
|
| 2025-11-12 |
详情>>
股本变动：
变动后总股本2186.95万股
|
| 2025-11-12 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-6.38美元,归母净利润-5735.2万美元,同比去年增长-17.67%
|
| 2025-08-27 |
复牌提示：
2025-08-27 06:55:00 停牌，复牌日期 2025-08-27 07:30:00
|
| 2025-08-12 |
详情>>
业绩披露：
2025年中报每股收益-4.17美元,归母净利润-2644.1万美元,同比去年增长24.65%
|
| 2025-05-12 |
详情>>
业绩披露：
2025年一季报每股收益-1.5美元,归母净利润-725.4万美元,同比去年增长72.92%
|
| 2025-03-28 |
详情>>
业绩披露：
2024年年报每股收益-23.51美元,归母净利润-5959.9万美元,同比去年增长66.71%
|
| 2025-02-07 |
详情>>
拆分方案：
每16.0000合并分成1.0000股
|
| 2024-12-30 |
股东大会：
将于2025-01-28召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our Amended and Restated Certificate of Incorporation, as amended (“Certificate of Incorporation”) to effect a reverse split of our outstanding common stock at a ratio in the range of 1-for-5 to 1-for-30 to be determined at the discretion of our Board of Directors, whereby each outstanding 5 to 30 shares would be combined, converted and changed into 1 share of our common stock, to enable the Company to comply with the Nasdaq Stock Market’s continued listing requirements (the “Reverse Stock Split Proposal”);
2.To authorize one or more adjournments of the special meeting to solicit additional proxies in the event there are insufficient votes to approve Proposal 1 described above (the “Adjournment Proposal”).
|
| 2024-11-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.29美元,归母净利润-4874万美元,同比去年增长68.92%
|
| 2024-11-14 |
财报披露：
美东时间 2024-11-14 盘前发布财报
|
| 2024-08-06 |
详情>>
业绩披露：
2024年中报每股收益-0.99美元,归母净利润-3509万美元,同比去年增长66.99%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-0.87美元,归母净利润-2679.1万美元,同比去年增长49.26%
|
| 2024-04-29 |
股东大会：
将于2024-06-10召开股东大会
会议内容 ▼▲
- 1.To elect Vimal Mehta, Ph.D. and Peter Mueller, Ph.D., as Class III directors to hold office until the Company’s annual meeting of stockholders to be held in 2027 and until their respective successors have been duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2024;
3.To approve, on an advisory (non-binding) basis, the compensation of our named executive officers (“Say-on-Pay Vote”);
4.To approve, on an advisory (non-binding) basis, the frequency of future Say-on-Pay Votes;
5.To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended (“Certificate of Incorporation”) to increase the number of authorized shares of common stock of the Company from 100,000,000 to 200,000,000;
6.To approve an amendment to the Certificate of Incorporation to provide for the exculpation of officers to the extent permitted by the General Corporation Law of the State of Delaware;
7.To approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal Nos. 5 and/or 6;
8.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment thereof.
|
| 2024-03-22 |
详情>>
业绩披露：
2023年年报每股收益-6.15美元,归母净利润-1.79亿美元,同比去年增长-8.02%
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-5.4美元,归母净利润-1.57亿美元,同比去年增长-41.32%
|
| 2023-08-14 |
详情>>
业绩披露：
2023年中报每股收益-3.68美元,归母净利润-1.06亿美元,同比去年增长-53.76%
|
| 2023-05-17 |
股东大会：
将于2023-06-26召开股东大会
会议内容 ▼▲
- 1.To elect Sandeep Laumas, M.D., Michael Miller and Michal Votruba, M.D., as Class II directors to hold office until the Company’s annual meeting of stockholders to be held in 2026 and until their respective successors have been duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2023;
3.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment thereof.
|
| 2022-04-05 |
股东大会：
将于2022-05-19召开股东大会
会议内容 ▼▲
- 1.to elect Krishnan Nandabalan, Ph.D. and June Bray as Class I directors to hold office until the Company’s annual meeting of stockholders to be held in 2025 and until their respective successors have been duly elected and qualified;
2.to ratify, in a non-binding vote, the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2022;
3.to transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-27 |
股东大会：
将于2021-06-11召开股东大会
会议内容 ▼▲
- 1.to elect Vimal Mehta, Ph.D. and Peter Mueller, Ph.D. as Class III directors to hold office until the Company’s annual meeting of stockholders to be held in 2024 and until their respective successors have been duly elected and qualified;
2.to ratify, in a non-binding vote, the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2021;
3.to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock of the Company from 50,000,000 to 100,000,000;
4.to approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 3;
5.to transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment thereof.
|
| 2020-04-06 |
股东大会：
将于2020-05-20召开股东大会
会议内容 ▼▲
- 1.to elect Sandeep Laumas, M.D. and Michal Votruba, M.D., Ph.D. as Class II directors to hold office until the Company’s annual meeting of stockholders to be held in 2023 and until their respective successors have been duly elected and qualified;
2.to ratify, in a non-binding vote, the appointment of BDO USA, LLP as our independent registered public accounting firm for 2020;
3.to approve the BioXcel Therapeutics, Inc. 2020 Incentive Award Plan;
4.to approve the BioXcel Therapeutics, Inc. 2020 Employee Stock Purchase Plan;
5.to transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment thereof.
|
| 2019-04-01 |
股东大会：
将于2019-05-23召开股东大会
会议内容 ▼▲
- 1.to elect Krishnan Nandabalan as a Class I director to hold office until our annual meeting of stockholders to be held in 2022 and until his respective successor has been duly elected and qualified;
2.to ratify, in a non-binding vote, the appointment of BDO USA, LLP as our independent registered public accounting firm for 2019;
3.to transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment thereof.
|